Jefferies Financial Group Inc. Purchases 475,000 Shares of MoonLake Immunotherapeutics $MLTX

Jefferies Financial Group Inc. boosted its position in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1,900.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 500,000 shares of the company’s stock after buying an additional 475,000 shares during the quarter. Jefferies Financial Group Inc.’s holdings in MoonLake Immunotherapeutics were worth $6,590,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $28,000. Bank of America Corp DE grew its stake in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after buying an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares during the last quarter. Covestor Ltd bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $46,000. Finally, BNP Paribas Financial Markets grew its stake in shares of MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after buying an additional 1,158 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Performance

Shares of MoonLake Immunotherapeutics stock opened at $18.19 on Tuesday. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -4.70 and a beta of 1.01. The company’s fifty day moving average is $17.44 and its 200 day moving average is $15.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07). Sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.71 EPS for the current year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 51,873 shares of the business’s stock in a transaction on Monday, April 13th. The shares were sold at an average price of $18.23, for a total value of $945,644.79. Following the sale, the chief executive officer owned 2,924,893 shares of the company’s stock, valued at $53,320,799.39. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bvf Partners L. P/Il sold 3,750,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the completion of the sale, the director directly owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,900,000 shares of company stock worth $65,714,663. 12.02% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of MoonLake Immunotherapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. BTIG Research reaffirmed a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, March 30th. Royal Bank Of Canada boosted their price target on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a report on Monday, March 2nd. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and raised their price objective for the company from $12.00 to $24.00 in a report on Monday, March 23rd. Finally, Needham & Company LLC raised their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.85.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.